VOTRIENT for Soft tissue sarcoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 16 adverse event reports in the FDA FAERS database where VOTRIENT was used for Soft tissue sarcoma.
Most Reported Side Effects for VOTRIENT
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 167 | 27.6% | 167 | 8 |
| Hypertension | 65 | 10.7% | 5 | 28 |
| Nausea | 59 | 9.7% | 9 | 29 |
| Diarrhoea | 54 | 8.9% | 4 | 21 |
| Fatigue | 52 | 8.6% | 10 | 21 |
| Vomiting | 44 | 7.3% | 6 | 26 |
| Decreased appetite | 40 | 6.6% | 6 | 20 |
| Investigation | 40 | 6.6% | 0 | 39 |
| Disease progression | 38 | 6.3% | 24 | 11 |
| Asthenia | 37 | 6.1% | 6 | 19 |
| Malaise | 22 | 3.6% | 3 | 11 |
| Abdominal pain | 20 | 3.3% | 2 | 8 |
| Hair colour changes | 20 | 3.3% | 0 | 7 |
| Platelet count decreased | 20 | 3.3% | 1 | 7 |
| Blood pressure increased | 18 | 3.0% | 2 | 10 |
Other Indications for VOTRIENT
Renal cancer (111)
Renal cell carcinoma (105)
Product used for unknown indication (97)
Sarcoma (24)
Renal cancer metastatic (22)
Leiomyosarcoma (21)
Metastatic renal cell carcinoma (21)
Neoplasm malignant (21)
Soft tissue cancer (13)
Angiosarcoma (12)
Other Drugs Used for Soft tissue sarcoma
PAZOPANIB (1,400)
DOXORUBICIN (302)
TAZEMETOSTAT HYDROBROMIDE (298)
IFOSFAMIDE (237)
CABOZANTINIB S-MALATE (192)
TRABECTEDIN (183)
NIVOLUMAB (156)
OLARATUMAB (156)
IMATINIB (124)
SUNITINIB MALATE (123)